Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus
- First Online:
- 140 Downloads
Mutations in the NPHS2 gene, which encodes podocin, are associated with steroid-resistant nephrotic syndrome in childhood. Renal histology frequently presents focal segmental glomerulosclerosis (FSGS). Post-transplant recurrence of proteinuria in patients affected by homozygous or compound heterozygous NPHS2 mutation is encountered rarely (1–2%) compared to 30% recurrence in nonhereditary FSGS. We report on a pediatric kidney transplant recipient with NPHS2-associated nephrotic syndrome and FSGS, who developed biopsy-proven recurrence of FSGS 10 years post-transplant in temporal association with conversion from cyclosporin A (CsA)- to sirolimus (SRL)-based immunosuppression, due to histological evidence of severe CsA-induced nephrotoxicity. Reswitch of the immunosuppressive regimen from SRL to CsA led to a noticeable decrease of proteinuria and to stabilization of graft function. We conclude that patients with hereditary FSGS are not entirely protected from post-transplant recurrence of proteinuria, even in the long term. The close temporal relationship of FSGS recurrence with CsA withdrawal and conversion to SRL suggests that caution should be exercised in the use of CsA-free immunosuppression also in patients with NPHS2-associated FSGS.
KeywordsFocal segmental glomerulosclerosis NPHS2 gene Cyclosporin A Sirolimus Podocin Nephrotic syndrome Proteinuria
- 9.Franz S, Faul C, Mundel PJ (2005) Cyclosporin protects podocyte stress fibers through stabilization of synaptopodin protein expression. J Am Soc Nephrol 16:Abstract SA-FC123Google Scholar
- 12.Takeda A, Morozumi K, Koyama K, Yoshida A, Uchida K, Tominaga Y, Haba T, Oikawa T, Usami T, Sugito K, Takeuchi O, Fujinami T, Yokoyama I, Tagaki H (1997) Severe cyclosporine arteriolopathy with focal segmental glomerulosclerosis is not a fatal finding in chronic renal allograft failure after year 5 of transplantation using cyclosporine. Transplant Proc 29:96–99CrossRefPubMedGoogle Scholar